The Use of N-Acetylcysteine in Respiratory Diseases

ISSN: 1875-6387 (Online)
ISSN: 1573-398X (Print)

Volume 13, 4 Issues, 2017

Download PDF Flyer

Current Respiratory Medicine Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Joseph Varon
The University of Texas Health Science Center
Houston, TX

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Use of N-Acetylcysteine in Respiratory Diseases

Current Respiratory Medicine Reviews, 9(5): 323-327.

Author(s): Shoshannah Levitt, Daniel Grupel, Maor Waldman, Tamir Tobias and Theodore K Marras.

Affiliation: Division of Internal Medicine, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, 84000, Israel.


N-acetylcysteine (NAC), the N-acetyl derivative of the amino acid cysteine, is perhaps best known for its wide use in the treatment of acetaminophen (paracetamol) toxicity, but it has been investigated for the treatment of myriad conditions. In this article we will review the uses of NAC in pulmonary diseases, the mechanism of action dosing, side effect profile and clinical implications in regard to COPD and idiopathic pulmonary fibrosis. One of the main targets of NAC is Inflammation and oxidative stress that are important factors in the pathogenesis of many chronic inflammatory lung disorders. While it is logical to conclude that the administration of antioxidants such as NAC will provide a mode of treatment for said conditions by targeting antioxidant-oxidant imbalance [8] and although the theory supporting the use of antioxidants is sound, it may not necessarily translate into clinical benefit. Based on the available evidence it is unlikely that mucolytics such as NAC will drastically affect symptoms, exacerbations or disease modification in COPD.


Interstitial lung diseases, N-Acetylcysteine, pulmonary diseases, side effects.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 5
First Page: 323
Last Page: 327
Page Count: 5
DOI: 10.2174/1573398X10666140204230324
Price: $58
13th Asthma & COPD

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science